Ionis Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Brett Monia
- Full Time Employees
- 1,480
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2855 Gazelle Court Carlsbad CA United States of America 92010
- IPO Date
- May 17, 1991
- CIK
- 0000874015
- Website
- ionis.com
- Similar Companies
- Business
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) develops and commercializes RNA-targeted therapeutics for patients with rare diseases and other unmet medical needs. The company utilizes its proprietary antisense technology platform to design drugs that modulate RNA and protein expression; its marketed products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Waylivra (volanesorsen) for rare cardiovascular and metabolic diseases; and its pipeline encompasses candidates such as pelacarsen for cardiovascular disease, olezarsen for familial chylomicronemia syndrome and familial partial lipodystrophy, and donidalorsen for hereditary angioedema. Ionis operates primarily in the biotechnology sector, targeting pharmaceutical companies through licensing agreements and direct commercialization in select markets, with global operations spanning the United States, Europe, and other regions. Founded in 1989 and headquartered in Carlsbad, California, the company maintains subsidiaries including Akcea Therapeutics, which focuses on commercializing certain antisense medicines prior to its integration into Ionis. In recent developments, Ionis completed the acquisition of certain assets from Novartis in 2024, including rights to pelacarsen; announced positive Phase 3 topline results for olezarsen in severe hypertriglyceridemia in mid-2025; and entered a strategic collaboration with Moderna in late 2024 to develop antisense-based therapies for cardiovascular indications. Additionally, the company reported its Q3 2025 financial results in November 2025, highlighting pipeline advancements and royalty revenues exceeding $200 million from Spinraza, alongside preparations for multiple regulatory filings in 2026.
Company News
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 1,357 Shares of Company Stock
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Alnylam vs. Ionis: Here's the Better Bad-News Buy
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week Low – Should You Sell?
Contrasting Alector (NASDAQ:ALEC) & Ionis Pharmaceuticals (NASDAQ:IONS)
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down After Analyst Downgrade